ReviewExpert opinion on therapeutic targets2020
Cholangiocarcinoma: novel therapeutic targets.
Registry-linked trialOpen access · greenAbstract readReview
In one paragraph
Review in Expert opinion on therapeutic targets, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07225452 (Liquid Biopsy Using Exosomal miRNA for Intrahepatic Cholangiocarcinoma Detection), which is not on this map. Cited by 27 papers.
0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Liquid Biopsy Using Exosomal miRNA for Intrahepatic Cholangiocarcinoma Detection
Who cites it
27 citing papers in PubMed, 42 citations in OpenAlex.
- Brusatol enhances the chemotherapy efficacy of Cisplatin and Gemcitabine in KKU-100 cholangiocarcinoma cells through ROS-mediated apoptosis.Scientific reports · 2026Article
- Molecular Mechanisms and Therapeutic Perspectives of Gut Microbiota, Autophagy, and Apoptosis in Cholangiocarcinoma Pathophysiology.International journal of molecular sciences · 2025Review
- Application and mechanism of anticancer peptides in organoid models of intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- Cancer-associated fibroblasts in cholangiocarcinoma: the central nexus of tumor-stroma crosstalk and therapeutic translation.Frontiers in immunology · 2025Review
- Enhanced ICOS Signaling Between Dendritic Cells and T Cells Characterizes the Immune Landscape of Human Cholangiocarcinoma.Human mutation · 2025Article
- Role of miRNA‑122 in cancer (Review).International journal of oncology · 2024Review
- RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.Biology direct · 2024Article
- Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.Frontiers in immunology · 2024Review
- Novel Adiponectin Receptor Agonist Inhibits Cholangiocarcinoma via Adenosine Monophosphate-activated Protein Kinase.Current medicinal chemistry · 2024Article
- Targeting polycomb repressor complex 2-mediated bivalent promoter epigenetic silencing of secreted frizzled-related protein 1 inhibits cholangiocarcinoma progression.Clinical and translational medicine · 2023Article
- The Arising Role of Extracellular Vesicles in Cholangiocarcinoma: A Rundown of the Current Knowledge Regarding Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2023Review
- Article
- Lanatoside C decelerates proliferation and induces apoptosis through inhibition of STAT3 and ROS-mediated mitochondrial membrane potential transformation in cholangiocarcinoma.Frontiers in pharmacology · 2023Article
- Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2.Oncology research · 2023Article
- A universal co-expression gene network and prognostic model for hepatic-biliary-pancreatic cancers identified by integrative analyses.FEBS open bio · 2022Article
- Review
- Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.The American journal of pathology · 2022Review
- Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression.Cell death discovery · 2022Article
- Exosome-transmitted miR-3124-5p promotes cholangiocarcinoma developmentFrontiers in oncology · 2022Article
- Overcome Drug Resistance in Cholangiocarcinoma: New Insight Into Mechanisms and Refining the Preclinical Experiment Models.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Keisaku SatoDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Shannon GlaserDepartment of Medical Physiology, Texas A&M University, College of Medicine, Bryan, Texas.
Domenico AlvaroGastroenterology, Medicine, Università Sapienza, Rome, Italy.
Fanyin MengDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Heather FrancisDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Gianfranco AlpiniDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Indiana University – Purdue University Indianapolis · USIndiana University School of MedicineBryan College · USSapienza University of Rome · IT
Funding
GROWTH REGULATION OF THE INTRAHEPATIC BILIARY TREER01DK054811 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2000 to 2021
$3.8MThe Paracrine Regulation of Mast Cells During Biliary/Cholangiocyte Repair and DamageR01DK108959 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI FRANCIS, HEATHER L · 2016 to 2024
$2.5MRegulation of Bile Duct Growth in Bile Duct Ligated RatsR01DK062975 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2005 to 2014
$1.9MRole of Sensory Neuropeptides in the Regulation of Biliary FunctionR01DK076898 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2008 to 2016
$1.8MThe Role of Stem Cell Derived Microvesicles in Cholestatic Liver InjuryR01DK107310 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2015 to 2019
$1.7MNeuroendocrine Regulation of Biliary Growth and FibrosisR01DK110035 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2017 to 2020
$1.2MRegulation of biliary growth and fibrosis by melatoninR01DK115184 · NIDDK · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, GLASER, SHANNON STROUD · 2017 to 2020
$1.2MREGULATION OF CELLULAR SENESCENCE BY NON-CODING RNAS IN ALCOHOLIC LIVER INJURYR21AA025997 · NIAAA · SCOTT AND WHITE MEMORIAL HOSPITAL · PI ALPINI, GIANFRANCO D, MENG, FANYIN · 2017 to 2018
$435kRole of stem cell derived microvesicles in alcoholic liver injuryR21AA025157 · NIAAA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ALPINI, GIANFRANCO D, MENG, FANYIN · 2017 to 2018
$350kBLR&D Research Career Scientist AwardIK6BX004601 · VA · RLR VA MEDICAL CENTER · PI ALPINI, GIANFRANCO D · 2019 to 2025
–Mechanisms of synergistic regulation of biliary inflammation and fibrosisI01BX003031 · VA · RLR VA MEDICAL CENTER · PI FRANCIS, HEATHER L · 2016 to 2023
–Functional characters of non-coding RNAs in alcoholic liver injuryI01BX001724 · VA · RLR VA MEDICAL CENTER · PI MENG, FANYIN · 2012 to 2024
–BLRD VA I01 BX000574BLRD VA I01 BX001724BLRD VA I01 BX003031BLRD VA IK6 BX004601NIAAA NIH HHS R21 AA025157NIAAA NIH HHS R21 AA025997NIDDK NIH HHS R01 DK054811NIDDK NIH HHS R01 DK062975NIDDK NIH HHS R01 DK076898NIDDK NIH HHS R01 DK107310NIDDK NIH HHS R01 DK108959NIDDK NIH HHS R01 DK110035NIDDK NIH HHS R01 DK115184
Abstract
PubMed holds no abstract for this paper.
Indexed as
Molecular Targeted TherapyAnimalsAntineoplastic AgentsBile Duct NeoplasmsCholangiocarcinomaDisease ProgressionDrug DevelopmentDrug Resistance, NeoplasmHumansMutationTumor MicroenvironmentAntineoplastic AgentsCholangiocarcinomaextracellular vesiclesimmunotherapylong non-coding RNAmicroRNAtumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07225452ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.